POSTOPERATIVE INCREASE IN SOLUBLE INTERLEUKIN-2 RECEPTOR SERUM LEVELS AS PREDICTOR FOR EARLY RECURRENCE IN NON-SMALL-CELL LUNG-CARCINOMA
POSTOPERATIVE INCREASE IN SOLUBLE INTERLEUKIN-2 RECEPTOR SERUM LEVELS AS PREDICTOR FOR EARLY RECURRENCE IN NON-SMALL-CELL LUNG-CARCINOMA
复制标题
DOI：
10.1002/1097-0142(19920515)69:10
复制
发表时间：
1992-05-15
期刊：
影响因子：
6.2
通讯作者：
TANCINI, G
中科院分区：
文献类型：
--
作者：
TISI, E;LISSONI, P;TANCINI, G
白细胞介素-2 （interleukin-2, IL-2）在激活宿主抗肿瘤免疫应答中起重要作用。除了IL-2细胞表面受体外，IL-2受体的可溶性形式（SIL-2R）可能在血液中释放，并可能参与IL-2可用性的调节。在肺癌患者中发现了高水平的SIL-2R。本研究评估围手术期血清SIL-2R水平变化对可手术非小细胞肺癌患者早期复发率的影响。该研究包括60例患者（表皮样癌33例，腺癌27例）。术前、术后7、30天采用酶免疫分析法测定血清SIL-2R水平。60例患者中有38例术后7天出现手术诱导的SIL-2R水平升高。术后第30天，32例（A组）患者SIL-2R值低于术前值，28例（B组）患者SIL-2R值高于术前值。中位随访10个月后，60例患者中有19例复发。B组复发率明显高于A组（28例16例，32例3例；P < 0.001）。这种差异在组织类型和节点状态方面也具有显著性。本研究表明，术后SIL-2R水平持续升高与可手术非小细胞肺癌患者较高的早期复发率相关。SIL-2R水平对复发的影响提示宿主免疫防御可能影响肺癌患者的临床病程。因此，围手术期SIL-2R的评估可能是可手术非小细胞肺癌预后的一个新的生物学因素。
It is known that interleukin-2 (IL-2) plays an important role in the activation of host antitumor immune response. In addition to IL-2 cell surface receptor, a soluble form of IL-2 receptor (SIL-2R) may be released in the blood and potentially be involved in the regulation of IL-2 availability. High SIL-2R levels have been found in patients with lung cancer. The current study evaluated the influence of changes in SIL-2R serum levels during the perioperative period on early relapse rate in patients with operable non-small cell lung cancer. The study included 60 patients (epidermoid carcinoma, 33; adenocarcinoma, 27). Serum levels of SIL-2R were measured with an enzyme immunoassay before surgery and 7 and 30 days after surgery. A surgery-induced increase in SIL-2R levels was seen 7 days after surgery in 38 of 60 patients. On the 30th day after surgery, SIL-2R values were lower than the preoperative values in 32 patients (Group A) or still greater in the other 28 patients (Group B). After a median follow-up of 10 months, relapse occurred in 19 of 60 patients. The relapse rate was significantly higher in Group B than in Group A patients (16 of 28 versus 3 of 32, respectively; P < 0.001). This difference also was significant in relation to histotype and node status. This study shows that the persistence of increased SIL-2R levels in the postoperative period is associated with a higher early relapse rate in patients with operable non-small cell lung cancer. The impact of SIL-2R levels on relapse suggests that host immune defenses may influence the clinical course of patients with lung cancer. Therefore, the evaluation of SIL-2R in the perioperative period may represent a new prognostic biologic factor in operable non-small cell lung cancer.